Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia | Blood Cancer Journal
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
HDAC deacethylation mechanism in leukemic cells . Overexpression of... | Download Scientific Diagram
Frontiers | Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia
Expression profiles of classes I, II, and IV HDACs and sensitivities to... | Download Scientific Diagram
2'-Fluoro-2'-deoxy-ara-C(Bz)-3'-phosphoramidite | Cytidine Analog | MedChemExpress
PRINCIPLES OF ANTINEOPLASTIC THERAPY
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
Cancers | Free Full-Text | HDAC Inhibitors in Acute Myeloid Leukemia
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition | Nature Chemical Biology
Clofarabine for the treatment of adult acute myeloid leukemia | Future Oncology
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy | Journal of Medicinal Chemistry
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia - ScienceDirect
![PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f668094fba2a13c35b48a8e49e9586d85158d88a/11-Figure6-1.png "PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar")
PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar
Conserved in vitro expression of HDAC repressors and modulators of ARAC... | Download Scientific Diagram
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy | Journal of Medicinal Chemistry
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long‐term outcome in European leukemia net favorable and intermediate‐risk acute myeloid leukemia -
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors | Chinese Medical Journal
Frontiers | Recent Update of HDAC Inhibitors in Lymphoma
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response | Leukemia
